STAT+: Startup BioAge raises $170 million Series D for Zepbound combination therapy

A California biotech developing a combination therapy with the blockbuster obesity drug Zepbound has raised a $170 million Series D round.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks